PE22898A1 - Formulaciones farmaceuticas - Google Patents
Formulaciones farmaceuticasInfo
- Publication number
- PE22898A1 PE22898A1 PE1996000831A PE00083196A PE22898A1 PE 22898 A1 PE22898 A1 PE 22898A1 PE 1996000831 A PE1996000831 A PE 1996000831A PE 00083196 A PE00083196 A PE 00083196A PE 22898 A1 PE22898 A1 PE 22898A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- replacement
- degree
- pharmaceutical formulations
- solubility
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001389 doxazosin Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 230000003628 erosive effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9523752.5A GB9523752D0 (en) | 1995-11-21 | 1995-11-21 | Pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE22898A1 true PE22898A1 (es) | 1998-05-07 |
Family
ID=10784188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1996000831A PE22898A1 (es) | 1995-11-21 | 1996-11-20 | Formulaciones farmaceuticas |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0862437A1 (is) |
| JP (1) | JPH10513481A (is) |
| KR (1) | KR19990071505A (is) |
| CN (1) | CN1215993A (is) |
| AP (1) | AP718A (is) |
| AR (1) | AR004335A1 (is) |
| AU (1) | AU709560B2 (is) |
| BG (1) | BG102438A (is) |
| BR (1) | BR9611626A (is) |
| CA (1) | CA2232715A1 (is) |
| CO (1) | CO4480020A1 (is) |
| CZ (1) | CZ155498A3 (is) |
| GB (1) | GB9523752D0 (is) |
| HR (1) | HRP960554A2 (is) |
| HU (1) | HUP9903734A3 (is) |
| IS (1) | IS4706A (is) |
| MA (1) | MA26410A1 (is) |
| MX (1) | MX9804008A (is) |
| NO (1) | NO982302L (is) |
| NZ (1) | NZ322053A (is) |
| OA (1) | OA10687A (is) |
| PE (1) | PE22898A1 (is) |
| PL (1) | PL326981A1 (is) |
| SK (1) | SK63098A3 (is) |
| TN (1) | TNSN96141A1 (is) |
| TR (1) | TR199800902T2 (is) |
| WO (1) | WO1997018814A1 (is) |
| YU (1) | YU62096A (is) |
| ZA (1) | ZA969722B (is) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| CA2314993A1 (en) * | 1997-12-16 | 1999-06-24 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
| AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
| GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
| EP0974343B1 (en) * | 1998-07-22 | 2004-09-29 | Pharma Pass II LLC | Process for manufacturing a solid metoprolol composition |
| EP0987020A1 (en) * | 1998-09-04 | 2000-03-22 | Pharma Pass LLC | Metoprolol composition and processes for manufacturing the same |
| CO5140079A1 (es) * | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
| UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| US20030059467A1 (en) * | 2001-09-14 | 2003-03-27 | Pawan Seth | Pharmaceutical composition comprising doxasozin |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| EP1680078A2 (en) * | 2003-10-17 | 2006-07-19 | Ranbaxy Laboratories, Ltd. | Oral matrix formulations of doxazosin |
| US20050255157A1 (en) * | 2004-05-11 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Sustained release, mucoadhesive vaginal pharmaceutical compositions |
| KR100574554B1 (ko) * | 2004-05-28 | 2006-04-27 | 한미약품 주식회사 | 니아신의 경구투여용 서방성 조성물 |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| KR100679111B1 (ko) * | 2004-11-20 | 2007-02-07 | 대우약품공업주식회사 | 독사조신을 포함하는 서방성 정제 |
| EP1919460A2 (en) * | 2005-08-22 | 2008-05-14 | Novartis AG | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| ES2360423T3 (es) | 2006-04-26 | 2011-06-03 | Supernus Pharmaceuticals, Inc. | Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal. |
| EP2540725A1 (de) | 2006-05-04 | 2013-01-02 | Boehringer Ingelheim International GmbH | Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| CN100396282C (zh) * | 2006-07-25 | 2008-06-25 | 山东省医药工业研究所 | 甲磺酸多沙唑嗪缓释胶囊及制备方法 |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| WO2009114648A1 (en) | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
| TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| KR101004205B1 (ko) | 2008-12-17 | 2010-12-24 | 동아제약주식회사 | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 |
| JP5685550B2 (ja) | 2009-02-13 | 2015-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用 |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| CN102481276A (zh) | 2009-04-20 | 2012-05-30 | 埃尔舍利克斯治疗公司 | 基于化学感受受体配体的治疗法 |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
| US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| MY161846A (en) | 2010-07-09 | 2017-05-15 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
| MX2013004364A (es) | 2010-10-19 | 2013-07-02 | Elcelyx Therapeutics Inc | Terapias a base de ligando del receptor quimiosensorial. |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| EP2661266B1 (en) | 2011-01-07 | 2020-09-16 | Anji Pharma (US) LLC | Chemosensory receptor ligand-based therapies |
| CN102058555A (zh) * | 2011-01-13 | 2011-05-18 | 北京汇诚瑞祥医药技术有限公司 | 一种多沙唑嗪控释片 |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| CN102188431A (zh) * | 2011-05-09 | 2011-09-21 | 浙江九旭药业有限公司 | 甲磺酸多沙唑嗪缓释片及其制备方法 |
| US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
| US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
| US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN105616378A (zh) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | 一种氟康唑胶囊及其制备方法 |
| CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
| US12097189B1 (en) | 2024-02-09 | 2024-09-24 | Astellas Pharma Inc. | Pharmaceutical composition for modified release |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1198386B (it) * | 1982-07-06 | 1988-12-21 | Lepetit Spa | Un prodotto a rilascio protratto contenente il suloctidile |
| US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| US4837111A (en) * | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
| IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| MX9100277A (es) * | 1990-07-23 | 1992-02-28 | Alza Corp | Dispositivo osmotico oral para aplicar nicotina |
-
1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
-
1996
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/xx unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/ko not_active Ceased
- 1996-11-11 CN CN96198486A patent/CN1215993A/zh active Pending
- 1996-11-11 SK SK630-98A patent/SK63098A3/sk unknown
- 1996-11-11 JP JP9519364A patent/JPH10513481A/ja active Pending
- 1996-11-11 NZ NZ322053A patent/NZ322053A/xx unknown
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Ceased
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/hu unknown
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/cs unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/pt not_active Application Discontinuation
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 PL PL96326981A patent/PL326981A1/xx unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-20 AR ARP960105252A patent/AR004335A1/es unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/es not_active Application Discontinuation
- 1996-11-20 YU YU62096A patent/YU62096A/sh unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/fr unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/xx unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/fr unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/hr not_active Application Discontinuation
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/es unknown
-
1998
- 1998-03-31 IS IS4706A patent/IS4706A/is unknown
- 1998-05-08 BG BG102438A patent/BG102438A/xx unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/no not_active Application Discontinuation
- 1998-05-20 MX MX9804008A patent/MX9804008A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA10687A (en) | 2002-11-27 |
| BG102438A (en) | 1999-01-29 |
| KR19990071505A (ko) | 1999-09-27 |
| HUP9903734A3 (en) | 2000-04-28 |
| TNSN96141A1 (fr) | 2005-03-15 |
| HUP9903734A2 (hu) | 2000-03-28 |
| CA2232715A1 (en) | 1997-05-29 |
| NZ322053A (en) | 1999-11-29 |
| CO4480020A1 (es) | 1997-07-09 |
| SK63098A3 (en) | 1999-05-07 |
| MX9804008A (es) | 1998-09-30 |
| GB9523752D0 (en) | 1996-01-24 |
| NO982302D0 (no) | 1998-05-20 |
| WO1997018814A1 (en) | 1997-05-29 |
| JPH10513481A (ja) | 1998-12-22 |
| AP9600883A0 (en) | 1997-01-31 |
| ZA969722B (en) | 1998-05-20 |
| CZ155498A3 (cs) | 1999-03-17 |
| TR199800902T2 (xx) | 1998-09-21 |
| AU7572196A (en) | 1997-06-11 |
| PL326981A1 (en) | 1998-11-09 |
| CN1215993A (zh) | 1999-05-05 |
| YU62096A (sh) | 1999-03-04 |
| IS4706A (is) | 1998-03-31 |
| AU709560B2 (en) | 1999-09-02 |
| EP0862437A1 (en) | 1998-09-09 |
| AP718A (en) | 1999-01-06 |
| AR004335A1 (es) | 1998-11-04 |
| HRP960554A2 (en) | 1998-02-28 |
| BR9611626A (pt) | 1999-06-01 |
| MA26410A1 (fr) | 2004-12-20 |
| NO982302L (no) | 1998-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE22898A1 (es) | Formulaciones farmaceuticas | |
| ES2349924T3 (es) | Composición de polisacáridos reticulados. | |
| US7943596B2 (en) | Medicinal composition for ophthal use containing acetylated hyaluronic acid | |
| DE69414840D1 (de) | Akzeptabele pharmazeutische zusammensetzung enthaltend einen alkohol und einen hydrophalischen wirkstoff | |
| PE20040675A1 (es) | Formulaciones de deposito de liberacion controlada | |
| US20130116328A1 (en) | Thermogelling Anaesthetic Compositions | |
| US10582915B2 (en) | Film for oral hemostasis and wound protection | |
| KR101066763B1 (ko) | 온도 반응성 전달계 | |
| ATE468848T1 (de) | In organischen lösemitteln lösliche biologisch abbaubare poly (alkylenoxid)- poly (p-dioxanon) blockcopolymere sowie diese enthaltende zusammensetzung zur arzneistoffverabreichung | |
| MX2014015902A (es) | Suministro de farmaco biodegradable para las composiciones hidrofobicas. | |
| CA2430481A1 (en) | Compositions for sustained delivery of hydrophobic drugs and process for the preparation thereof | |
| CN116437897A (zh) | 口腔水凝胶组合物和用途 | |
| ECSP17081071A (es) | Composiciones de matriz polimérica tópicas que comprenden una alta concentración de hialuronato de sodio bio-fermentado y sus usos | |
| US9345779B2 (en) | Aqueous ophthalmic composition | |
| ES2399166T3 (es) | Formulaciones tópicas antivíricas en la forma de un gel bio-adhesivo | |
| FI923385A0 (fi) | Foerfarande foer framstaellning av en oral farmaceutisk sammansaettning som innehaoller cyklosporin. | |
| JPH0859512A (ja) | フィルムコーティング組成物およびそれを用いた固形製剤 | |
| CN103211755A (zh) | 无菌稳定的阿奇霉素滴眼液的生产方法 | |
| Mao et al. | A review on in situ gels as polymer drug carriers in the treatment of periodontitis | |
| Khokhlenkova | Prospects of using biopolymeric films in medicine and pharmacy | |
| CN109381442B (zh) | 药物载体及应用其的药物传递系统 | |
| ZA202401325B (en) | Formulations with enhanced sn-38 solubility and oral absorption | |
| KR100666220B1 (ko) | 구내염 치료용 분사제 조성물 | |
| ECSP961944A (es) | Formulaciones farmaceuticas | |
| TW202617149A (zh) | 具有增強的ｓｎ－３８溶解度及經口吸收的調配物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |